Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest update is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics Limited has announced an investor webinar scheduled for May 30, 2025, to update shareholders on its progress in Q2 2025. The company is advancing several drug development programs, including treatments for Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, Autosomal Dominant Polycystic Kidney Disease, and Phelan McDermid Syndrome. These programs are at various stages of clinical trials, with significant milestones anticipated in 2025 and 2026, potentially impacting the company’s market position and stakeholder interests.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. Utilizing a proprietary drug delivery platform, the company aims to enhance the potency of precision medicines within the RNA therapeutic class. PYC’s drug development programs target monogenic diseases, which have a higher likelihood of success in clinical development.
Average Trading Volume: 529,074
Technical Sentiment Signal: Buy
Current Market Cap: A$729.1M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.